Compositions and methods of treating neurological disorder and stress-induced conditions
AssigneeAnn & Robert H. Lurie Children's Hospital of Chicago
InventorJhumku D. Kohtz
Life of this patent
Estimating the term…
Abstract
The present disclosure provides the use of Akr1b8, an agonist of Akr1b8, Akr1B10, or an agonist of Akr1B10 in methods and compositions for the treatment of neurological disorders and stress-induced conditions. Methods of increasing the levels of 5Thr3a on neuronal cells is also provided by contacting the neuronal cells with Akr1b8, an agonist of Akr1b8, Akr1B10, or an agonist of Akr1B10.
Claims6
A method of increasing expression of 5-hydroxytryptamine receptor 3A (5Htr3a) in at least one interneuron in a subject having a developmental neurological disorder or mood disorder treated with serotonin regulation, the method comprising:
- contacting the at least one interneuron with an effective amount of at least one of aldo-keto reductase family 1, member B8 (Akr1B8), an expression vector encoding Akr1B8, aldo-keto reductase family 1, member B10 (Akr1B10), or an expression vector encoding Akr1B10, wherein the at least one interneuron exhibits an increase expression of 5Htr3a.
Dependencies are inferred from the claim text.